Insys Therapeutics Inc (NASDAQ:INSY) Excited After Getting The Final DEA Rule

0
510
Insys Therapeutics Inc

Insys Therapeutics Inc (NASDAQ:INSY), one of the Biotech Stocks Picks, has come to the limelight to make the announcement regarding the Drug Enforcement Agency’s move to issue an interim final rule that would lead to Syndros™ eventual placement in Schedule II of the Controlled Substances Act.

On July 1, 2016, the New Drug Application for Syndros gained approval from the Food and Drug Administration.

The Chief Medical Officer who is at the same time the CEO for Insys, Dr. Santosh Vetticaden has expressed great optimism in taking the high end new product to the various chemotherapy patients which will in deed do much towards helping face out their vomiting and nausea not forgetting AIDS patients with anorexia that comes with a major cut in weight.

As a matter of fact, the company may soon be holding talks with FDA In a bid to finalize on labeling and subsequent launch of Syndros which is set to happen in the second half of 2017.It is important to point out to the fact that the use of dronabinol could at times result in cognitive and psychiatric effects. Eventually, one may end up with mental or physical impairment.

In the case of patients suffering from cardiac disorders, it may get a lot worse considering that they may end up with tachycardia, hypertension, hypotension and syncope. The disulfiram-like reaction experience after is quite discomforting.

It goes without saying that Insys Therapeutics Inc has impacted many lives around the globe with its innovative drugs as well as with its novel drug delivery systems of therapeutic molecules.

The company’s board is dedicated to offering great leadership that will help propel the company to higher levels of business success through developing working solutions to the various acute health complications.

The high end provider has succeeded in developing medications to treat epilepsy and the rest of the complications with unmet needs. The company, which is one of the Top Biotech Stocks, has a lot of plans underway, and all of them are expected to propel the giant drug provider to the highest levels of business success!

LEAVE A REPLY

Please enter your comment!
Please enter your name here